Recently, Li et al. reviewed current candidate lncRNA for targeted therapy including MALAT1 (with both an oncogenic and tumor-suppressive role), TYMOS, GATA3-AS1, TINCR, SNHG16, and lncRNA Xist (all promote immune escape or immunosuppression) [302]. The gene discussed is MALAT1; the disease is neoplasm.